Panasci LC - Search Results

1

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH Jr, Panasci LC. Sahebjam S, et al. Among authors: panasci lc. Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4. Br J Cancer. 2011. PMID: 21970880 Free PMC article.

2

Double antibody radioimmunoassay for monitoring metastatic breast cancer.

Schecter RL, Major PP, Kovac PE, Ishida M, Kovalik EC, Dion AS, Langleben A, Boileau G, Boos G, Panasci L, et al. Schecter RL, et al. Br J Cancer. 1988 Sep;58(3):362-7. doi: 10.1038/bjc.1988.220. Br J Cancer. 1988. PMID: 3179189 Free PMC article.

3

Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.

Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R. Panasci L, et al. Clin Cancer Res. 2001 Mar;7(3):454-61. Clin Cancer Res. 2001. PMID: 11297233 Review.

4

In vitro evidence for homologous recombinational repair in resistance to melphalan.

Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R, Panasci LC. Wang ZM, et al. Among authors: panasci lc. J Natl Cancer Inst. 2001 Oct 3;93(19):1473-8. doi: 10.1093/jnci/93.19.1473. J Natl Cancer Inst. 2001. PMID: 11584063

5

The role of DNA repair in nitrogen mustard drug resistance.

Panasci L, Xu ZY, Bello V, Aloyz R. Panasci L, et al. Anticancer Drugs. 2002 Mar;13(3):211-20. doi: 10.1097/00001813-200203000-00002. Anticancer Drugs. 2002. PMID: 11984064 Review.

6

Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia.

Bello VE, Aloyz RS, Christodoulopoulos G, Panasci LC. Bello VE, et al. Among authors: panasci lc. Biochem Pharmacol. 2002 May 1;63(9):1585-8. doi: 10.1016/s0006-2952(02)00954-1. Biochem Pharmacol. 2002. PMID: 12007561

7

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.

Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC. Xu Z, et al. Among authors: panasci lc. Anticancer Drugs. 2002 Jun;13(5):511-9. doi: 10.1097/00001813-200206000-00010. Anticancer Drugs. 2002. PMID: 12045463

8

Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.

Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, Panasci L. Aloyz R, et al. Cancer Res. 2002 Oct 1;62(19):5457-62. Cancer Res. 2002. PMID: 12359753

9

SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.

Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH Jr, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E. Panasci L, et al. J Clin Oncol. 2003 Jan 15;21(2):232-40. doi: 10.1200/JCO.2003.03.047. J Clin Oncol. 2003. PMID: 12525514 Clinical Trial.

10

Imatinib sensitizes CLL lymphocytes to chlorambucil.

Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L. Aloyz R, et al. Leukemia. 2004 Mar;18(3):409-14. doi: 10.1038/sj.leu.2403247. Leukemia. 2004. PMID: 14712290

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143 results

Search Page

Filters